Glucagon counterregulation (GCR) is a key protection against hypoglycemia that is compromised in diabetes. In β-cell-deficient rats, GCR pulsatility can be amplified if insulin (INS) or somatostatin (SS) are infused in the pancreatic artery and then switched off during hypoglycemia. The data indicate that these signals act by different mechanisms, and here we analyze the differences between the two switch offs (SOs) and predict the GCR-amplifying effect of their individual or combined application.
Methods:
A minimal control network (MCN) of α/δ-cell interactions is approximated by differential equations to explain the GCR response to a SO and test in silico the hypotheses: (i) INS SO suppresses basal and pulsatile, while SS SO blocks only pulsatile glucagon release and (ii) simultaneous application of the two switch offs will augment the individual GCR response.
Results:
The mechanism postulated in (i) explains the differences in the GCR responses between the SOs. The MCN predicts that simultaneous application of INS and SS decreases basal glucagon but increases post-SO amplitude, thus doubling the response of GCR achieved by each of the individual signals.
Conclusion:
The current analyses predict that INS and SS SOs improve defective GCR in β-cell deficiency through different but complementary mechanisms and suggest SO strategies to maximally enhance GCR in type 1 diabetes by simultaneous manipulation of the network control. These results are clinically relevant, as they could have application to design of an artificial pancreas by providing ways to augment GCR that would not require glucagon infusion.
CryerPEGerichJE. Relevance of glucose counterregulatory systems to patients with diabetes: critical roles of glucagon and epinephrine. Diabetes Care.1993;6 (1): 95–9.
2.
GerichJE. Lilly lecture 1988. Glucose counterregulation and its impact on diabetes mellitus. Diabetes.1988;37 (12): 1608–17.
3.
CryerPE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev.1999;15 (1): 42–6.
4.
CryerPE. Hypoglycemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia.2002;45 (7): 937–48.
5.
BreljeTCScharpDWSorensonRL. Three-dimensional imaging of intact isolated islets of Langerhans with confocal microscopy. Diabetes.1989;38 (6): 808–14.
6.
KleinmanRGingerichRWongHWalshJLloydKOhningGDe GiorgioRSterniniCBrunicardiFC. Use of the Fab fragment for immunoneutralization of somatostatin in the isolated perfused human pancreas. Am J Surg.1994;167 (1): 114–9.
7.
SamolsEStagnerJI. Intra-islet regulation. Am J Med.1988;85 (5A): 31–5.
StagnerJISamolsEMarksV. The anterograde and retrograde infusion of glucagon antibodies suggests that A cells are vascularly perfused before D cells within the rat islet. Diabetologia.1989;32 (3): 203–6.
ZhouHTranPOYangSZhangTLeRoyEOseidERobertsonRP. Regulation of alpha-cell function by the beta-cell during hypoglycemia in Wistar rats: the “switch-off” hypothesis. Diabetes.2004;53 (6): 1482–7.
12.
HopeKMTranPOZhouHOseidELeroyERobertsonRP. Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the “switch-off” hypothesis. Diabetes.2004;53 (6): 1488–95.
13.
ZhouHZhangTOseidEHarmonJTonookaNRobertsonRP. Reversal of defective glucagon responses to hypoglycemia in insulin-dependent autoimmune diabetic BB rats. Endocrinology.2007;148 (6): 2863–9.
14.
ZhouHZhangTHarmonJSBryanJRobertsonRP. Zinc, not insulin, regulates the rat α-cell response to hypoglycemia in vivo.Diabetes.2007;56 (4): 1107–12.
15.
FarhyLSDuZZengQVeldhuisPPJohnsonMLBraymanKLMcCallAL. Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats. Am J Physiol Endocrinol Metab.2008;295 (3): E575–85.
16.
FarhyLS. Modeling of oscillations in endocrine networks with feedback. Methods Enzymol.2004;384: 54–81.
17.
BrunicardiFCAtiyaAMoldovanSLeeTCFaganSPKleinmanRMAdrianTECoyDHWalshJHFisherWE. Activation of somatostatin receptor subtype 2 inhibits insulin secretion in the isolated perfused human pancreas. Pancreas.2003;27 (4): e84–9.
18.
BrunicardiFCKleinmanRMoldovanSNguyenTHWattPCWalshJGingerichR. Immunoneutralization of somatostatin, insulin, and glucagon causes alterations in islet cell secretion in the isolated perfused human pancreas. Pancreas.2001;23 (3): 302–8.
19.
CejvanKCoyDHEfendicS. Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes.2003;52 (5): 1176–81.
20.
KlaffLJTaborskyGJJr.Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia. Diabetes.1987;36 (5): 592–6.
21.
KleinmanRGingerichROhningGWongHOlthoffKWalshJBrunicardiFC. The influence of somatostatin on glucagon and pancreatic polypeptide secretion in the isolated perfused human pancreas. Int J Pancreatol.1995;18 (1): 51–7.
22.
LudvigsenEOlssonRStridsbergMJansonETSandlerS. Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem.2004;52 (3): 391–400.
23.
Portela-GomesGMStridsbergMGrimeliusLObergKJansonET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol.2000;8 (2): 126–32.
24.
SchuitFCDerdeMPPipeleersDG. Sensitivity of rat pancreatic A and B cells to somatostatin. Diabetologia.1989;32 (3): 207–12.
25.
StrowskiMZParmarRMBlakeADSchaefferJM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology.2000;141 (1): 111–7.
26.
TironeTANormanMAMoldovanSDeMayoFJWangXPBrunicardiFC. Pancreatic somatostatin inhibits insulin secretion via SSTR-5 in the isolated perfused mouse pancreas model. Pancreas.2003;26 (3): e67–73.
27.
BrunicardiFCElahiDAndersenDK. Splanchnic neural regulation of somatostatin secretion in the isolated perfused human pancreas. Ann Surg.1994;219 (3): 258–66.
28.
DumonteilEMagnanCRitz-LaserBKtorzaAMedaPPhilippeJ. Glucose regulates proinsulin and prosomatostatin but not proglucagon messenger ribonucleic acid levels in rat pancreatic islets. Endocrinology.2000;141 (1): 174–80.
29.
EpsteinSBerelowitzMBellNH. Pentagastrin and glucagon stimulate serum somatostatin-like immunoreactivity in man. J Clin Endocrinol Metab.1980;51 (6): 1227–31.
30.
HayashiMYamadaHUeharaSMorimotoRMuroyamaAYatsushiroSTakedaJYamamotoAMoriyamaY. Secretory granule-mediated co-secretion of L-glutamate and glucagon triggers glutamatergic signal transmission in islets of Langerhans. J Biol Chem.2003;278 (3): 1966–74.
31.
Tapia-ArancibiaLAstierH. Glutamate stimulates somatostatin release from diencephalic neurons in primary culture. Endocrinology.1988;123 (5): 2360–6.
32.
UtsumiMMakimuraHIshiharaKMoritaSBabaS. Determination of immunoreactive somatostatin in rat plasma and responses to arginine, glucose and glucagon infusion. Diabetologia1979;17 (5): 319–23.
33.
FujitaniSIkenoueTAkiyoshiMMakiTYadaT. Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas. Metabolism.1996;45 (2): 184–9.
34.
GöpelSOKannoTBargSRorsmanP. Patch-clamp characterisation of somatostatin-secreting -cells in intact mouse pancreatic islets. J Physiol.2000;528 (Pt 3): 497–507.
35.
HermansenKChristensenSEOrskovH. Characterization of somatostatin release from the pancreas: the role of potassium. Scand J Clin Lab Invest.1979;39 (8): 717–22.
ItoKMaruyamaHHiroseHKidoKKoyamaKKataokaKSarutaT. Exogenous insulin dose-dependently suppresses glucopenia-induced glucagon secretion from perfused rat pancreas. Metabolism.1995;44 (3): 358–62.
38.
RavierMARutterGA. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha cells. Diabetes.2005;54 (6): 1789–97.
39.
Van SchravendijkCFForiersAVan den BrandeJLPipeleersDG. Evidence for the presence of type I insulin-like growth factor receptors on rat pancreatic A and B cells. Endocrinology.1987;121 (5): 1784–8.
40.
FarhyLSStraumeMJohnsonMLKovatchevBVeldhuisJD. A construct of interactive feedback control of the GH axis in the male. Am J Physiol Regul Integr Comp Physiol.2001;281 (1): R38–51.
41.
FarhyLSStraumeMJohnsonMLKovatchevBVeldhuisJD. Unequal autonegative feedback by GH models the sexual dimorphism in GH secretory dynamics. Am J Physiol Regul Integr Comp Physiol.2002;282 (3): R753–64.
42.
FarhyLSVeldhuisJD. Putative GH pulse renewal: periventricular somatostatinergic control of an arcuate-nuclear somatostatin and GH-releasing hormone oscillator. Am J Physiol Regul Integr Comp Physiol.2004;286 (6): R1030–42.
43.
FarhyLSVeldhuisJD. Joint pituitary-hypothalamic and intrahypothalamic autofeedback construct of pulsatile growth hormone secretion. Am J Physiol Regul Integr Comp Physiol.2003;285 (5): R1240–9.
44.
GenterPBermanNJacobMIppE. Counterregulatory hormones oscillate during steady-state hypoglycemia. Am J Physiol.1998;275 (5 Pt 1): E821–9.
45.
BergstenP. Pathophysiology of impaired pulsatile insulin release. Diabetes Metab Res Rev.2000;16 (3): 179–91.
46.
BergstenP. Role of oscillations in membrane potential, cytoplasmic Ca2+, and metabolism for plasma insulin oscillations. Diabetes.2002;51Suppl 1: S171–6.
47.
BertsALiuYJGylfeEHellmanB. Oscillatory Ca2+ signaling in somatostatin-producing cells from the human pancreas. Metabolism.1997;46 (4): 366–9.
48.
JaspanJBLeverEPolonskyKSVan CauterE. In vivo pulsatility of pancreatic islet peptides. Am J Physiol.1986;251 (2 Pt 1): E215–26.
49.
TaborskyGJJr.AhrénBHavelPJ. Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. Diabetes.1998;47 (7): 995–1005.
50.
GerichJELangloisMNoaccoCKaramJHForshamPH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science.1973;182 (108): 171–3.
51.
HoffmanRPArslanianSDrashALBeckerDJ. Impaired counterregulatory hormone responses to hypoglycemia in children and adolescents with new onset IDDM. J Pediatr Endocrinol.1994;7 (3): 235–44.
52.
SegelSAParamoreDSCryerPE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes.2002;51 (3): 724–33.
53.
BanarerSMcGregorVPCryerPE. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes.2002;51 (4): 958–65.
54.
MüllerWAFaloonaGRUngerRH. Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med.1973;54 (1): 52–7.
55.
ReavenGMChenYDGolayASwislockiALJaspanJB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab.1987;64 (1): 106–10.
56.
UngerRHOrciL. Glucagon and the A cell: physiology and pathophysiology. N Engl J Med.1981;304 (25): 1518–24.
57.
El-KhatibFHJiangJGerrityRGDamianoER. Pharmacodynamics and stability of subcutaneously infused glucagon in a type 1 diabetic swine model in vivo.Diabetes Technol Ther.2007;9 (2): 135–44.
